A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Completed · Phase 1

Conditions studied: Healthy, Obese, Overweight, Obesity

In brief

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Key facts

Study ID: NCT06440980
Run by: Eli Lilly and Company
People needed: 533
Starts: 2024-06-24
Expected to finish: 2025-06-02
Last updated by the study team: 2026-07-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Participants who are overtly healthy as determined by medical history and physical examination.
Have a stable body weight for one month prior to screening (less than or equal to 5 percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40 kilogram per meter square (kg/m²).
Participants must be reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
Have venous access sufficient to allow for blood sampling.

You may not qualify if…

Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.
Have a history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or other significant active, uncontrolled medical conditions.
Have significant history of or currently have major depressive disorder or psychiatric disorder within the last 2 years.
Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome.
Have known clinically significant gastric emptying abnormality.
Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer.
Have an abnormal 12-lead electrocardiogram (ECG) at screening.
Have history of pancreatitis.
Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]).
Have difficulty swallowing capsules or tablets.

Where it is running

Anaheim Clinical Trials, LLC — Anaheim, California, United States
Collaborative Neuroscience Research, LLC — Los Alamitos, California, United States
Fortrea Clinical Research Unit — Daytona Beach, Florida, United States
Altasciences Company Inc. — Overland Park, Kansas, United States
QPS — Springfield, Missouri, United States
Fortrea Clinical Research Unit — Dallas, Texas, United States
Fortrea Clinical Research Unit — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.